Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy
M Santarpia, A Liguori, N Karachaliou… - Lung Cancer: Targets …, 2017 - Taylor & Francis
The discovery of epidermal growth factor receptor (EGFR) mutations and subsequent
demonstration of the efficacy of genotype-directed therapies with EGFR tyrosine kinase …
demonstration of the efficacy of genotype-directed therapies with EGFR tyrosine kinase …
Safety of osimertinib in EGFR-mutated non-small cell lung cancer
L Mezquita, A Varga, D Planchard - Expert Opinion on Drug Safety, 2018 - Taylor & Francis
Introduction: Osimertinib is a third-generation epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor (TKI), specifically designed to inhibit EGFR sensitizing and T790M …
tyrosine kinase inhibitor (TKI), specifically designed to inhibit EGFR sensitizing and T790M …
Osimertinib making a breakthrough in lung cancer targeted therapy
H Zhang - OncoTargets and therapy, 2016 - Taylor & Francis
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the evidence-
based first-line treatment for advanced non-small-cell lung cancer that harbors sensitizing …
based first-line treatment for advanced non-small-cell lung cancer that harbors sensitizing …
[HTML][HTML] A consensus on the role of osimertinib in non-small cell lung cancer from the AME Lung Cancer Collaborative Group
T Jiang, C Su, S Ren, F Cappuzzo… - Journal of Thoracic …, 2018 - ncbi.nlm.nih.gov
The first-and second-generation epidermal growth factor receptor tyrosine kinase inhibitors
(EGFR-TKIs) have brought substantial clinical benefit to patients with advanced non-small …
(EGFR-TKIs) have brought substantial clinical benefit to patients with advanced non-small …
Osimertinib for EGFR T790M mutation-positive non-small cell lung cancer
K Soejima, H Yasuda, T Hirano - Expert review of clinical …, 2017 - Taylor & Francis
Introduction: Significant advances have been made since the development of epidermal
growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) targeting EGFR mutations in …
growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) targeting EGFR mutations in …
Osimertinib: first global approval
SL Greig - Drugs, 2016 - Springer
Abstract Osimertinib (Tagrisso™, AZD9291) is an oral, third-generation epidermal growth
factor receptor tyrosine kinase inhibitor (EGFR TKI) that is being developed by AstraZeneca …
factor receptor tyrosine kinase inhibitor (EGFR TKI) that is being developed by AstraZeneca …
[HTML][HTML] Osimertinib as first-line therapy in advanced NSCLC: a profile of its use
LJ Scott - Drugs & Therapy Perspectives, 2018 - Springer
Osimertinib (Tagrisso®) is an oral, CNS-active, third-generation epidermal growth factor
receptor (EGFR) tyrosine kinase inhibitor (TKI) that selectively inhibits EGFR TKI-activating …
receptor (EGFR) tyrosine kinase inhibitor (TKI) that selectively inhibits EGFR TKI-activating …
Osimertinib for patients with poor performance status and EGFR T790M mutation-positive advanced non-small cell lung cancer: a phase II clinical trial
Osimertinib is a molecularly targeted agent used to treat non-small cell lung cancer
(NSCLC) patients with an epidermal growth factor receptor (EGFR) T790M mutation …
(NSCLC) patients with an epidermal growth factor receptor (EGFR) T790M mutation …
[HTML][HTML] Treating disease progression with osimertinib in EGFR-mutated non-small-cell lung cancer: novel targeted agents and combination strategies
V Di Noia, A D'aveni, E D'argento, S Rossi… - ESMO open, 2021 - Elsevier
Highlights•Acquired resistance mechanisms to osimertinib can be EGFR dependent or
independent.•First-and fourth-generation EGFR-TKIs are able to overcome EGFR …
independent.•First-and fourth-generation EGFR-TKIs are able to overcome EGFR …
[HTML][HTML] Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC
D Planchard, PA Jänne, Y Cheng… - … England Journal of …, 2023 - Mass Medical Soc
Background Osimertinib is a third-generation epidermal growth factor receptor–tyrosine
kinase inhibitor (EGFR-TKI) that is selective for EGFR-TKI–sensitizing and EGFR T790M …
kinase inhibitor (EGFR-TKI) that is selective for EGFR-TKI–sensitizing and EGFR T790M …